login

Double-Blind, Placebo-Controlled Trial of Divalproex Monotherapy in the Treatment of Symptomatic Youth at High Risk for Developing Bipolar Disorder

The Journal of Clinical PsychiatryPublished 15 May 2007
Robert L. Findling, Thomas Frazier, Eric A. Youngstrom, Nora McNamara, Robert J. Stansbrey, Barbara Gracious
Citations118
SJR quartileQ1
SJR score1.49
SNIP1.38

TL;DR

The results suggest that, although well tolerated, divalproex sodium does not produce clinically meaningful improvements in the treatment of symptomatic youths suffering from either bipolar NOS or cyclothymia who are at genetic risk for developing bipolar disorder.

Abstract

These results suggest that, although well tolerated, divalproex sodium does not produce clinically meaningful improvements in the treatment of symptomatic youths suffering from either bipolar NOS or cyclothymia who are at genetic risk for developing bipolar disorder.

Keywords

PsychologySocial SciencesMedicine